Breaking News, Collaborations & Alliances

Intravacc Partners with Wageningen Bioveterinary Research and Utrecht University

Aim to develop an intranasal COVID-19 vaccine with a NDV vector

By: Contract Pharma

Contract Pharma Staff

Intravacc, a translational research and development vaccine institutes, with a track record in developing viral and bacterial vaccines, has announced more details on its development of an intranasal vaccine against COVID-19. The vaccine will be developed through a newly established public private partnership that combines the vaccine development technology from Intravacc, the viral vector technology and animal technologies from Wageningen Bioveterinary Research (WBVR) based in the Netherlands, a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters